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Skeletal muscles undergoing atrophy have decreased [ATP], PGC-1α expression, and 
mitochondrial content. This combination of findings is unexpected because decreased [ATP] is 
often associated with greater [AMP] and subsequent activation of AMPK, a known inducer of 
PGC-1α activity and mitochondrial biogenesis. A possible explanation is increased enzyme 
activity of AMP Deaminase 3 (AMP → IMP + NH3), which is highly overexpressed in atrophic 
muscles and functions to prevent increases in [AMP]. We tested the hypothesis that AMPD3 
overexpression would significantly attenuate DNP (mitochondria uncoupler) induced 
phosphorylation of AMPK(Thr172) and PGC-1α promotor activity through regulation of 
intracellular energetics (ATP, ADP, AMP). Methods: Myotubes were transduced with 
adenoviruses encoding AMPD3 or GFP (control) and then treated for 1 h with 0.6mM 2,4 
dinitrophenol (DNP). Nucleotides, amino acids, and proteins were extracted immediately after 
DNP treatment and measured by UPLC and Western Blot. To confirm DNP was not toxic, 
myotubes were washed, and samples were collected 1 h later for nucleotides and amino acids. To 
determine the effect of AMPD3 overexpression on PGC-1α promotor activity we transfected 




GFP overexpression and a 4-day 100μM DNP treatment, we measured luciferase activity. We 
also stained myotubes for mitochondria using a green fluorescent dye (MitoTracker green FM) 
and quantified the percentage of pixels positive for florescence. Results: DNP treatment resulted 
in a 40% decline in [ATP], and increased [ADP] (1.4-fold), [AMP] (13.8-fold), AMP:ATP ratio 
(24-fold), and [IMP] (from undetectable) (p<0.001). DNP treatment also significantly increased 
phosphorylated AMPK(Thr172) (6.1-fold), and phosphorylation of downstream AMPK targets, 
ACC (Ser79, 4.8-fold) and ULK1 (Ser555, 2-fold) (p<0.001). Aspartic acid levels increased 7.1-
fold (p<0.001), suggesting decreased activity of the purine nucleotide cycle (IMP + aspartic acid 
→→ AMP). As expected, myotubes that were overexpressing AMPD3 had significantly 
attenuated increases in [ADP] (1.1-fold), [AMP] (5.3-fold), and the AMP:ATP ratio (9.6-fold) 
(p<0.001), and this was reflected by significantly less phosphorylated AMPK(Thr172) (p<0.05). 
No changes were measured in aspartic acid or phosphorylation of ACC(Ser79) and 
ULK1(Ser555) between myotubes overexpressing AMPD3 versus GFP. After a 1 h recovery 
[AMP], AMP:ATP ratio, and [aspartic acid] were no different than vehicle treated, 
demonstrating recovery of energetics and cell viability. Long-term treatment with DNP 
significantly increased PGC-1α promotor activity (1.4-fold, p<0.001) compared to vehicle 
groups, while 5 days of AMPD3 overexpression significantly decreased PGC-1α promotor 
activity (1.3-fold, p<0.005) compared to GFP. Long-term DNP treatment increased the 
percentage of pixels positive for green florescence (p<0.05), however, myotubes overexpressing 
AMPD3 had significantly less than controls (p<0.01). Conclusions: Since activation of AMPK 
and PGC-1α are critical for increasing mitochondrial biogenesis, our results suggest that 
overexpression of AMPD3, such as occurs during muscle atrophy, is an important contributor to 
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Chapter 1: Introduction 
 
 In skeletal muscle, chronic increases in protein degradation result in substantial decreases 
in muscle mass, strength, and endurance in a process referred to as muscle atrophy. Muscle 
atrophy is a degenerative condition that can occur progressively with aging1,2, rapidly with 
complete disuse or starvation3–5, and pathologically with diseases such as cancer, diabetes, heart 
failure, and chronic kidney disease6–9. The onset of muscle atrophy during these conditions is a 
significant contributor to disability and mortality10–12.  
 In addition to decreases in contractile proteins, muscles undergoing atrophy have 
decreased mitochondrial content4,6,13 and cellular energetics3,13–16, which is defined by decreases 
in the concentrations of high-energy phosphates: ATP or PCr, and increases in their degradation 
products: ADP, AMP, creatine, and Pi. Together, these result in muscles with diminished 
oxidative capacity, endurance, and force production11,17,18. These negative consequences of 
muscle atrophy and impairments in muscle function ultimately combine to decrease the 
individual’s exercise capacity, which is also a powerful predictor of mortality11,19. Furthermore, 
exercise and muscle contractions during daily activities are critical for maintaining muscle mass, 
and the implementation of exercise interventions during disease can significantly improve 
clinical outcome2,20–22. Therefore, investigating the cellular mechanisms that contribute to 
decreased mitochondrial content is necessary for the identification of drug targets or therapeutic 
strategies that can preserve mitochondria and muscle function. In turn, this will help to maintain 
exercise capacity, ability to perform activities of daily living, and delay mortality in patients 
experiencing muscle atrophy.   
 Mitochondrial content is largely dependent on the balance between mitochondrial 




mitochondrial biogenesis are activated in response to decreased cellular energetics25,26. In 
particular, increases in [AMP] have been shown to increase phosphorylation of AMP-activated 
protein kinase (AMPK), which in turn increases activation and expression of  PGC-1α, 
ultimately resulting in mitochondrial biogenesis26–29. Muscles from several different atrophy 
models have decreased energetics3,13–16, however, despite this, PGC-1α expression is decreased 
during atrophy30–32. Interestingly, chemical activation of AMPK via AICAR (an AMP mimetic) 
is sufficient to increase PGC-1α expression and preserve mitochondrial proteins during 
denervation induced atrophy30. This suggests that during atrophy AMPK is not activated and a 
possible explanation is that [AMP] is not increased due to increased enzyme activity of AMP 
Deaminase 3 (AMPD3).   
 Skeletal muscles from several different models of muscle atrophy have significantly 
upregulated AMPD3 expression, evident by a 5-100-fold increase in mRNA content, 3-fold 
increase in protein content, and a 34% increase in enzyme activity31,33. AMPD catalyzes the 
deamination of AMP to IMP with the release of ammonia as a byproduct (AMP → IMP + 
NH₃)34.  Therefore, increased activity of AMPD3 could potentially regulates mitochondrial 
content in skeletal muscle by decreasing [AMP], phosphorylation of AMPK, PGC-1α 
expression, and mitochondrial biogenesis. However, the effect of AMPD3 overexpression on 
these different markers of mitochondrial biogenesis is unknown.  
 Using C2C12 myotubes as a model of skeletal muscle, we sought to determine whether 
overexpression of AMPD3 was sufficient to attenuate increases in [AMP], phosphorylation of 
AMPK(Thr172), PGC-1α promotor region activity, and mitochondrial content caused by 
increased energy demand. As a model of energy, demand we used chemical treatment with the 




mitochondrial inner membrane and decreases oxidative phosphorylation efficiency. We 
hypothesize that AMPD3 overexpression will attenuate DNP-induced increases in [AMP], 
phosphorylation of AMPK(Thr172), and PGC-1α promotor region activity. This will decrease 




Chapter 2: Literature Review 
Skeletal Muscle Atrophy 
 Muscle atrophy is characterized by smaller muscle fibers and fewer mitochondria, 
resulting in substantial loss of muscle mass, strength, and endurance 17,18,35. Whether a muscle 
undergoes hypertrophy or atrophy is dependent on the balance between protein synthesis versus 
protein degradation. In skeletal muscle, signaling for protein synthesis is mediated through the 
phosphoinositide 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) pathway 36,37. 
On the other hand, protein degradation is largely regulated by the transcription factor forkhead 
box protein O (FOXO), which controls the expression of several atrophy related genes 31,38,39. 
Besides the FOXO family (FOXO1 & FOXO3), other transcription factors such as, SMAD2, 
SMAD3, NF-κB, along with glucocorticoids are known to regulate protein degradation 40–42.  
 There are two dominant cellular mechanisms involved in protein degradation: the 
autophagy-lysosome and the ubiquitin-proteasome systems 43,44. Protein degradation by the 
ubiquitin-proteasome system involves the attachment of a polyubiquitin chain to targeted 
proteins by E3 ligases 45. After being tagged with a polyubiquitin chain the proteins are unfolded 
and degraded by the proteasome complex 43. Protein degradation by the autophagy-lysosome 
system involves the expansion of an autophagosome around proteins and organelles which then 
merge with the acidic lysosome to degrade proteins 44. During atrophy the genes encoding for 
many components and regulators of these proteolytic mechanisms (ubiquitin ligases, proteasome 
subunits, autophagy mediating proteins) are significantly increased 31,36. Protein degradation, 
especially the ubiquitin-proteasome system, is highly dependent on energy in the form of ATP 
45–47. Both ubiquitination of proteins and the unfolding/degradation of proteins by the proteasome 




proteasome mediated degradation 45,46, demonstrating the importance of cellular energetics on 
the control of overall protein content.  
Mitochondrial content is decreased during atrophy 
 Atrophic muscles have decreased mitochondrial content and a depressed energy state 
(decreased [ATP] and/or increases in [ADP], [Pi]), which results in muscles with decreased 
specific force (force normalized to cross sectional area) and endurance 3,15–18,48.  This has clinical 
relevance considering low oxidative capacity is associated with increased risk of cardiovascular 
disease and mortality 49,50, as well as, the development of insulin resistance and type 2 diabetes 
6,51,52.  
 Atrophy of myofibers and decreases in mitochondrial content occur during several 
common pathologies, including cancer 17,53,54, diabetes 6,55, and renal failure 7,48,56. During 
cancer, 50-80% of patients can experience cachexia (chronic inflammation caused by pathology 
that causes muscle wasting), and almost 80% of those patients experiencing cachexia will die 
within 1 year of diagnosis 9,21,54. These cancer cachectic muscles have impaired metabolic 
function and abnormal mitochondria13. Patients with type 2 diabetes mellitus experience muscle 
atrophy 6,55 along with reductions in PGC-1α and mRNA for oxidative phosphorylation 
proteins31,57, resulting in decreased oxidative capacity and weaker muscles 58. Patients with renal 
failure also experience substantial losses of muscle mass along with decreased mitochondrial and 
PGC-1α content 48,59. 
 Taken together, these studies show that muscle atrophy and decreased mitochondrial 
content are a consequence of disuse (denervation) and numerous chronic diseases (cancer, 





Regulation of Mitochondrial Biogenesis 
 Skeletal muscle is a dynamic tissue capable of changing its contractile properties and 
substrate utilization in response to various mechanical stimuli and metabolic demands. During 
repeated muscle contractions (i.e. physical activity/exercise) there is an increase in skeletal 
muscle ATP hydrolysis leading to increases in ADP, AMP, and Pi
34,60
. This increase in metabolic 
demand can be sensed through increases in intracellular [AMP], Ca2+,  and [NAD+]/[NADH] by 
several enzymes such as AMP activated protein kinase (AMPK), calcium/calmodulin-dependent 
protein kinase (CaMK), and silent mating-type information regulation 2 homolog 1 (SIRT1) 26,61–
63 These enzymes respond to the decrease in energetics by activating the highly effective 
activator of mitochondrial biogenesis, PGC-1α (Figure 1) 29,63,64  
 
 
Figure 1.  A) Muscle 
contractile activity alters the 
concentration of several 
metabolites and molecules 
involved in initiating 
mitochondrial biogenesis, 
including increasing the ratios 
of AMP/ATP and 
NAD+/NADH, as well as 
cytosolic calcium. These 
changes enhance the activity 
of a number of kinases (B), 
including AMPK, CaMK, and 
the deacetylase SIRT1. (C) 
These proteins increase the 
activation and expression of 
the transcriptional co-activator 
PGC-1α, which increases 
mitochondrial biogenesis by 
enhancing transcription of 
mitochondrial proteins.  
 





AMPK regulation of mitochondrial biogenesis 
 When the rate of ATP hydrolysis exceeds the rate of ATP re-synthesis, such as that 
occurs during repeated muscle contractions or hypoxia, intracellular [ADP] increases. 
Furthermore, [AMP] also increases because of the near-equilibrium adenylate kinase (AK) 
reaction (ADP+ADP ↔ ATP+AMP) 65. The increase in [AMP] and decrease in [ATP] activates 
the important cellular “energy sensor” AMP-activated protein kinase (AMPK)28. AMPK is a 
heterotrimeric Ser/Thr kinase composed of one catalytic (α) and two regulatory subunits (β,γ) . 
Activation of AMPK is enhanced upon the binding of its γ subunit by AMP, which increases the 
catalytic activity of the molecule and enhances phosphorylation of its α subunit Thr172 residue 28. 
Several in vivo studies have investigated the effect of allosteric activation of AMPK on 
mitochondrial content 25,26,66. Winder et al. subcutaneously injected rats with AICAR (when 
phosphorylated functions as an AMP mimetic and activates AMPK) and observed an increase in 
AMPK activity, along with an increase in cytochrome C and  δ-aminolevulinate (ALA) synthase 
(ALA is mitochondrial matrix enzyme required for biosynthesis of heme, which is essential for 
electron transfer) in the quadriceps and soleus muscles. These muscles also exhibit a significant 
increase in citrate synthase, malate dehydrogenase, and succinate dehydrogenase (common 
markers of mitochondrial content). A similar study by Bergeron et al. used β-
guanadinoproprionic acid (β-GPA) (a creatine homolog) to activate AMPK25.  β-GPA works by 
competing for the transport of creatine, decreasing intracellular creatine content, inhibiting 
creatine kinase reaction, and therefore, reducing the energy buffering capacity of the muscle. In 
rats fed a diet supplemented with β-GPA, there is >85% reduction in muscle phosphocreatine 
and a ~40-50% reduction in ATP. After a 9 week diet (45% fat, 1% β-GPA) rats fed with β-GPA 




compared to controls. Furthermore, there was a ~75% increase in ALA synthase mRNA and a 
significant increase in Cytochrome C content compared to controls. In addition to the evidence 
of increased mitochondrial content, Narkar et al. found that chronically activating AMPK via 4 
weeks of oral AICAR treatment increased running endurance by 44% compared to controls 66. 
  In contrast to experimental activation of AMPK, others have generated muscle-specific 
null mice for AMPK β1 and β2 subunits (β1β2M-KO) to investigate the loss of AMPK activity 
in skeletal muscle metabolism67. Muscles of these mice have significant decreases in 
mitochondrial content and function as evident by ~30% decrease in cytochrome c oxidase 
activity, ~47% decrease in succinate dehydrogenase (SDH) activity, and ~56% in mitochondrial 
DNA copy number. Taken together these studies demonstrate that activation of AMPK is an 
important and potent regulator of mitochondrial content and function. 
CaMK regulation of mitochondrial biogenesis 
 A hallmark of muscle contractions is an increase in intracellular Ca2+ ions. Because of its 
critical role in muscle contraction, researchers were led to investigate the effect of Ca2+ levels on 
mitochondrial biogenesis 62,63,68,69. Increasing intracellular Ca2+  in vitro via treatment with Ca2+ 
ionophores or caffeine (stimulates release of Ca2+ from sarcoplasmic reticulum) induces the 
expression of mitochondrial genes68,69. The increase in intracellular Ca2+ activates calcium 
dependent enzymes such calcineurin and calcium/calmodulin-dependent protein kinase (CaMK), 
which are known to signal expression of oxidative fiber-type genes 63. Therefore, it seemed 
logical that CaMK was involved in the signaling of mitochondrial biogenesis, and Wu et al. 
developed transgenic mice that expressed a muscle-specific constitutively active form of CaMK 
isoform IV in hopes to elucidate the specific mechanism63. The CaMK mice had substantially 




Microarrays of gene expression found increases in mRNA of several mitochondrial proteins such 
as NADH dehydrogenase, cytochrome B, cytochrome C, and Carnitine Palmitoyltransferase-1 
(CPT-1) compared to wild-type. Furthermore, the transgenic mice had increased expression of 
PGC-1α and the proximal promotor region of the PGC-1α gene was activated 4-fold higher in 
CaMKIV active C2C12 myotubes. These studies demonstrate that contractile activity associated 
increases in intracellular Ca2+ signals for mitochondrial biogenesis through a CaMK-PGC-1 
transcriptional mechanism.  
SIRT1 regulation of mitochondrial biogenesis 
 Another mechanism by which contractile activity signals for mitochondrial biogenesis is 
through activation of silent mating-type information regulation 2 homolog 1 (SIRT1) 61,70,71. 
Sirtuins are deacetylase enzymes that are activated by increases in intracellular NAD+/NADH 
concentrations. SIRT1 has been shown to regulate mitochondrial biogenesis through 
deacetylation of downstream targets such as PGC-1α and HIF-1α64. Interestingly, SIRT1 activity 
is also regulated by AMPK through AMPK mediated increases in [NAD+] 61,64,72. 
PGC-1α regulation of mitochondrial biogenesis 
AMPK, CaMK, and SIRT1 regulate mitochondrial content through activation of the 
transcriptional coactivator, peroxisome proliferator-activated receptor γ co-activator-1α (PGC-
1α)23. PGC-1α is widely considered a potent regulator of mitochondrial biogenesis as it is 
sufficient to induce mitochondrial biogenesis and is activated by several cellular signaling 
pathways all related to contractile activity and increased metabolic demand 30,73,74.  PGC-1α 
exists in the cytosol and once activated translocates to the nucleus where it activates transcription 
of its own mRNA, as well as, numerous transcription factors including nuclear respiratory 




transcription factors then increase the expression of genes involved in mitochondrial biogenesis 
such as NuGEMPs (mitochondrial proteins encoded in nuclear DNA), mtDNA (mitochondrial 
proteins encoded in mitochondrial DNA), and numerous oxidative metabolism genes.. 
 PGC-1α was first discovered as a coactivator of PPARγ in studies examining differential 
gene expression in brown adipose tissue during response to cold-induced adaptive 
thermogenesis76.Transgenic mice that overexpress PGC-1α in skeletal muscle demonstrate 
greater voluntary exercise activity and significantly higher aerobic capacities, as determined by 
peak VO2 consumption, compared to wild-type mice 
75. Calvo et al. also measured mitochondrial 
protein content and found that PGC-1α transgenic mice had expansive increases in proteins 
involved in fatty acid oxidation and oxidative phosphorylation. Enzymatic activity of citrate 
synthase was higher in both gastrocnemius and tibialis anterior muscles, signifying functional 
increases of mitochondria. 
 Similarly, PGC-1α knockout mice have reduced mitochondrial content, function, and 
mitochondrial gene expression 27,77. Handschin et al. generated muscle-specific PGC-1α 
knockout mice and then measured markers of mitochondria content and function. There was a 
reduction of mRNA for several mitochondrial proteins and enzymes. The mice had decreased 
voluntary exercise compared to wild-type controls as well as a 28% decrease in total time till 
exhaustion on a treadmill indicating decreased muscle endurance and aerobic capacity. Taken 
together, these studies demonstrate why PGC-1α is considered a master regulator of 
mitochondrial biogenesis.  
Regulation of Mitochondrial Degradation 
 Maintaining the functional capacity of mitochondria requires the coordinated process of 




(autophagy of mitochondria) and incorporating newly synthesized proteins back into the 
mitochondrial matrix 24. Mitophagy is critical to maintain mitochondria capable of preserving 
energy homeostasis and healthy skeletal muscle 24,78. 
 In congruence with their regulation of mitochondrial biogenesis, AMPK and SIRT1 also 
function to regulate mitophagy. Activation of AMPK has been shown to induce mitophagy by 
direct phosphorylation of unc-51-like kinase 1 (ULK1) on serine 317, 555, and 777 residues 79,80. 
Phosphorylation of ULK1 is the first reaction in a signaling cascade leading to the recruitment, 
expansion, and formation of the autophagosome. Activated SIRT1 is shown to contribute to 
mitophagy through deacetylation of autophagy-related gene 7 (Atg7) which is critical for 
autophagosome membrane expansion81. The effect of AMPD3 overexpression on AMPK and 
SIRT1 mediated autophagy is unknown.  
The role of AMP Deaminase 
 During high energy demanding conditions the hydrolysis of ATP can increase 100 fold60. 
When ATP hydrolysis outpaces synthesis, cellular ATP content declines and ADP and AMP 
accumulate. The increase in [ADP] and [AMP] activate the enzymatic reactions of adenylate 
kinase (ADP+ADP↔ATP+AMP) and AMP deaminase (AMP→IMP+NH3). Together, these 
reactions serve to limit the accumulation of [ADP] and [AMP] in order to maintain the ATP: 
ADP: AMP ratios, and preserve the energy state of the cell 65. Along with maintaining the 
relative ratios of adenine nucleotides, AMPD catalyzes the entry reaction of the purine 
nucleotide cycle (Figure 2). The purine nucleotide cycle is a multistep process that generates 
citric acid cycle intermediates while catalyzing the reamination of IMP 82,83.  Activity of the 




of AMPD1 expression in skeletal muscle have been suggested to impair muscle function through 
reduced purine nucleotide cycle activity83,84. 
AMP Deaminase increased during atrophy  
  Using microarray hybridization of cDNA, differential mRNA expression for genes 
involved in muscle atrophy were quantified 31,32,85. These studies mapped a common 
transcriptional profile for most if not all types of muscle atrophy (denervation, starvation, cancer-
cachexia, diabetes, renal failure) and allowed for the identification of novel transcriptional 
changes that occur during rapid muscle loss. Along with predictable genes involved in protein 
synthesis and degradation, 
genes involved in energy 
metabolism were also 
identified. In general, the 
mRNA for genes involved in 
ATP synthesis (including PGC-
1α), glycolysis, and ketone 
metabolism were significantly 
reduced. Conversely, an increase in mRNA expression was measured for genes encoding 
glutamine synthase, IMP dehydrogenase 2, and AMP deaminase isoform 3. Surprisingly, 
AMPD3 had one of the largest increases in expression, being 5-100 fold increased depending on 
the atrophy condition. These findings are similar to an earlier in vivo study’s findings that upon 
denervation induced atrophy, total AMPD activity increased by 34% and the protein content of 
AMPD3 increased three-fold 33. Increased expression of AMPD3 is significant for mitochondrial 
biogenesis considering that AMPD would be expected to bind and/or degrade AMP, lower 
Figure 2. AMP Deaminase is the entry reaction into the 




intracellular [AMP], thus, inhibit activation of AMPK. The general role of AMPD3 during 


























 Atrophic muscles from multiple conditions (denervation, diabetes, cancer cachexia, 
starvation, renal failure) have decreases in intracellular ATP and creatine phosphate levels 3,13–16. 
Normally this would result in activation of several energy sensing molecules, most notably 
AMPK, which would in turn activate and increase PGC-1α content subsequently leading to 
increased mitochondrial biogenesis23. However, atrophic muscles have decreased PGC-1α and 
mitochondrial content despite having depressed energetics31. Chemical activation of AMPK 
during atrophy via AICAR resulted in increased PGC-1α and mitochondrial content30 suggesting 
that atrophic muscles are still capable of responding to AMPK but the main signal, [AMP], is 
undetected. 
 We hypothesize that increased AMPD3 expression limits the accumulation of AMP 
within the cell and attenuates signaling for mitochondrial biogenesis. Therefore the purpose of 
this study was to determine the effect of overexpressing AMPD3 on adenine nucleotides, AMPK 





1) To determine if AMPD3 overexpression is sufficient to decrease [AMP] and phosphorylation 
AMPK(Thr172) in C2C12 myotubes both at rest and during a short-term energy demand. 
2) To determine if AMPD3 overexpression decreases PGC-1α promotor activity in C2C12 
myotubes 
↑ AMPD3 ↓ [AMP] ↓ AMPK ↓ PGC-1α ↓ Mito. 




Chapter 3: Methods 
Experimental Design 
  In order to test our hypothesis that AMPD3 attenuates increases in [AMP] and 
phosphorylation of AMPK(Thr172), we overexpressed AMPD3 in C2C12 myotubes for 24 hours 
using adenovirus. At hour 23, we treated myotubes with of 0.6 mM 2,4 dinitrophenol (DNP) for 
1 hour, to reduce cellular energetics (↓[ATP], ↑[ADP], ↑[AMP]) and stimulate AMPK 
phosphorylation. We used this model to stimulate AMPK, compared to direct chemical 
activation, because we believe that increased AMPD activity is an upstream regulator of AMPK. 
Thus, directly activating AMPK using chemical activators (such as AICAR) would not increase 
[AMP] and bypass the AMPD reaction. Furthermore, nucleotides and proteins were collected 
immediately after treatment to determine changes in energetics and protein phosphorylation. 
Nucleotides were collected again at 1 hour post DNP treatment to ensure cell viability. To 
determine long-term effects of AMPD3 on PGC-1α expression we transfected myoblasts with a 
2kb PGC-1α -Luciferase reporter, differentiated myotubes, and then chronically expressed 
AMPD3 (5days) and treated with continuous DNP (4days).    
Cell Culture 
C2C12 mouse myoblasts were grown on gelatin-coated 6-well plates in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% fetal bovine serum, penicillin (100 μg /mL), and 
streptomycin (100 μg/mL) until 75-90% confluent. Media was then switched to DMEM with 2% 
horse serum and penicillin/streptomycin to allow for differentiation into multi-nucleated 
myotubes. Four days after differentiation, myotubes were transduced with adenovirus encoding 
AMPD3-GFP or GFP (Vector Biolabs). Twenty-four hours after transduction myotubes were 




Nucleotides were collected on ice by PCA extraction immediately after. For recovery 
measurements, myotubes were washed twice with phosphate buffered saline (PBS), given fresh 
differentiation media, and then nucleotides were collected 1 hour after washing. For long-term 
treatment experiments, myotubes were differentiated and virus was transduced 24 hours later. 
Twenty-four hours after transduction myotubes were treated chronically with a 100 µM DNP 
dosage. Every 24 hours the media was exchanged with a fresh DNP+DMEM solution to ensure 
chronic uncoupling. To confirm virus transduction efficiency, GFP florescence was checked 
every 24 hours using florescent microscopy.  
Western blot analysis 
  Proteins were extracted from cells in radio-immunoprecipitation (RIPA) buffer including 
protease inhibitors (Roche, complete) and quantified by BCA Assay (Pierce). Equal amounts of 
protein (7.3 μg/well) were separated by SDS-PAGE (10% polyacrylamide) then transferred to 
polyvinylidene difluoride (PVDF) membranes. Equal loading and transfer was confirmed by 
Ponceau S staining. Membranes were blocked for 1 hour at room temperature using a 5% BSA 
dissolved in TBS-T solution. Primary antibodies were purchased from ABCAM (AMPD3; 
ab118230), Cell Signaling (AMPKα #5831; pAMPK thr172 #2531, ULK1 #DH85, pULK1 
ser555 #DIH4), and Millipore (pACC ser79 Lot #JC1938937). Antibodies were diluted in a 
solution of tris-buffered saline 0.1% tween-20 (TBS-T) with 2% bovine serum albumin. 
Membranes were incubated in primary antibody overnight at 4°C.  Secondary antibodies 
conjugated to horseradish peroxidase (Cell Signaling #7074, ThermoFisher #31444) were 
detected with Western Chemiluminesence HRP Substrate (EMD Millipore). Band intensities 




(Bio-Rad). Approximate molecular weights of protein were calculated relative to PageRuler Plus 
protein ladder (ThermoFisher). 
Nucleotide and Aspartic acid Measurements  
C2C12 myotubes were washed twice with ice cold PBS, and nucleotides were extracted 
in ice cold 0.5 N PCA + 5mM EDTA and stored in Eppendorf tubes. After sonication, 
precipitated proteins were pelleted by centrifugation (10,000 rpm for 10 minutes at 4°C) and the 
supernatant removed. Supernatants were neutralized by the addition of ice cold 1 N KOH and 
centrifugation at 4°C to remove potassium-perchlorate salt. Supernatants were stored at -80°C 
until analysis. Protein pellets were re-suspended in 0.2 N NaOH for protein estimation by BCA 
Assay (Pierce).  
Adenine nucleotide concentrations (ATP, ADP, AMP) and degradation products (IMP, 
adenine, and inosine) are determined by ultra-performance liquid chromatography (UPLC) using 
a Waters Acquity UPLC H-Class system and an Acquity UPLC HSS T3 1.8 μm, 2.1 mm X 150 
mm column (Waters) as done previously 86. 
Aspartic acid was measured by UPLC using the AccQ-Tag Ultra Derivitization kit 
(Waters).  PCA extracts were diluted in a borate buffer and then combined with AccQ tag 
reagent. After incubation at 55°C, the amine group of aspartic acid is labeled with 6-
aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC), which makes this amino acid easily 
detectable using UV absorbance.    
Reporter activity 
 To measure PGC-1α promotor activity, myoblasts were transfected with plasmids 
encoding a 2kb PGC-1α promotor-firefly luciferase (addgene, plasmid #8887, as described by 27) 




transfection myoblasts were switched to differentiation media. To determine luciferase activity 
we followed the Promega Dual-Luciferase Reporter Assay protocol. Briefly, myotubes are 
washed twice with PBS, and then passive lysis buffer is added. After a 15-30 minute incubation 
at room temperature, cell lysates are collected. Firefly and renilla luciferase activity are 
measured separately as instructed by Promega. Luciferase activity is normalized to renilla values.  
Microscopy Imaging 
 To stain for mitochondria area and nuclei, myotubes were treated with 100 nM of 
MitoTracker Green FM (Life Technologies) and 2 µg/ml Hoescht 33343 (nuclei) dissolved in 
differentiation media. After 30 minutes of incubation at 37°C, growth media was switched to 
FlouroBrite DMEM and fluorescent images were captured using filters typically used for GFP 
and DAPI. Mitochondria area was quantified using ImageJ software. After subtracting the 
background, images were converted to binary and the percent of positive pixels was quantified.  
Statistics 
Significant differences between DNP concentrations were determined by a one way ANOVA 
and Tukey’s post hoc analysis test with p<0.05. Significant differences between the 4 
experimental groups (Vehicle+GFP, Vehicle+AMPD3, DNP+GFP, DNP+AMPD3) was 
determined using a 2x2 ANOVA with p<0.05. PGC-1α reporter data was analyzed using an 
unpaired two-tailed t-test between experimental groups with significance set at p<0.05. Data was 




Chapter 4: Results 
Effects of short-term AMPD3 overexpression on adenine nucleotide metabolism and AMPK. 
In order to test the effect of AMPD3 overexpression on the activation of AMPK, we 
needed establish a condition of energy demand that would be sufficient to decrease cellular 
energetics and specifically cause increases in the concentration of AMP. To do this we treated 
myotubes with the mitochondrial uncoupler 2,4 dinitrophenol (DNP). To determine an 
appropriate dosage of DNP, we treated C2C12 myotubes with 0, 0.4, 0.6, 0.8, and 1 mM DNP, 
and collected samples 1 hour later for measurement of nucleotides (Figure 1). Increasing DNP 
concentrations resulted in a progressive decrease in [ATP], ranging from 45.0 µmol/g protein in 
vehicle (methanol) treated to 16.8 µmol/g at 1 mM DNP (Fig. 1a). As expected, [ADP] increased 
with DNP, peaking at 8.3 µmol/g with 0.6 mM DNP, but interestingly decreased to 6.5 and 5.3 
µmol/g with 0.8 and 1 mM DNP (Fig. 1b). [AMP] doubled from 0.34 µmol/g in vehicle to 0.68 
µmol/g at 0.4 mM, but then rose markedly with increasing DNP concentrations peaking at 7.8 
µmol/g, a 23-fold increase versus vehicle (Fig. 1c). The decreases in [ATP] and increases in 
[AMP] subsequently resulted in a nearly 60-fold increase in the AMP:ATP ratio, from a value of 
0.008 in vehicle to 0.46 in 1 mM DNP groups (Fig. 1d). Similar to [AMP], [IMP] rose with 
increasing concentrations of DNP, ranging from undetectable in vehicle to 4.7 µmol/g at 1 mM 
DNP (Fig. 1e). Total adenine nucleotides and IMP (AN+IMP) decreased linearly from 49.8 
µmol/g in vehicle to 34.6 µmol/g at 1 mM DNP (Fig. 1f), which suggests that nucleotides (AMP 
and IMP) were further metabolized to nucleosides (adenosine or inosine). From these findings 
we concluded that 0.6 mM DNP would be most appropriate dose to test our hypothesis because it 
significantly increased [ADP] (1.8-fold), [AMP] (6-fold), and the AMP:ATP (9-fold) compared 




the AMP:ATP ratio. Furthermore, 0.6 mM DNP resulted in modest reductions of AN+IMP from 
49.8 in vehicles to 45.3 as opposed to larger decreases with 0.8 and 1 mM DNP. 
After determining the optimal DNP dose, we then tested the effect of acutely 
overexpressing AMPD3 (24 hrs.) and treatment with or without DNP (1 hr.) on intercellular 
concentration of adenine nucleotides and IMP (Figure 2). To control for any effect of adenovirus 
transduction and general effects of protein overexpression, we transduced myotubes with an 
adenovirus overexpressing GFP. Furthermore, to control for any effect of the DNP solvent 
methanol, we treated vehicle groups with equal volumes of methanol. Therefore, we had four 
experimental groups: vehicle-GFP, vehicle-AMPD3, DNP-GFP, and DNP-AMPD3. After 24 
hours of AMPD3 and 1 hour of DNP, veh-AMPD3 had significantly less (1.3-fold) [ATP] 
compared to veh-GFP, while DNP-AMPD3 had significantly less (1.5-fold) [ATP] compared to 
DNP-GFP. AMPD3 overexpression also resulted in significantly less [ADP] in both vehicle (1.4-
fold) and DNP (2-fold) groups. As predicted DNP-AMPD3 had significantly less (6.3-fold) 
[AMP] compared to DNP-GFP. This was reflected by a significantly attenuated increase in the 
AMP:ATP, with DNP-GFP groups experiencing a 24-fold increase compared to veh-GFP, while 
DNP-AMPD3 experiencing only a 9-fold increase compared to veh-AMPD3. Veh-AMPD3 had 
0.41 µmol/g [IMP] compared to undetectable for veh-GFP, signifying basal AMPD activity, and 
DNP-AMPD3 had significantly greater (2.9-fold) [IMP] compared to DNP-GFP. Veh-AMPD3 
had significantly less (1.2-fold) AN+IMP compared veh-GFP, and similarly DNP-AMPD3 had 
significantly less (1.4-fold) compared to DNP-GFP.  
These findings show that both AMPD3 and DNP can significantly decrease the total 
adenine nucleotide pool within the cell of which could have potentially lethal consequences. 




steady-state levels after DNP. To test this we treated myotubes with 0.6 mM DNP for 1 hour, 
washed twice and switched to DNP free media, and then collected nucleotides at 1 hour post 
DNP treatment (Figure 3). DNP groups had significantly less [ATP] than vehicle groups, yet no 
differences existed between GFP and AMPD3 (Fig. 3a). DNP groups had significantly less 
[ADP] than vehicle groups, and DNP-GFP had significantly less (1.5-fold) [ADP] than DNP-
AMPD3 (Fig. 3b). Notably [ADP] from DNP-GFP was 3-fold less than levels measured 
immediately after DNP treatment. No differences were measured in [AMP] between vehicle and 
DNP groups or AMPD3 and GFP (Fig 3c). However, similar to [ADP], [AMP] concentrations 
returned back to pre-DNP levels and this resulted in AMP:ATP ratio also returning back to 
previous values (Fig. 3d). This trend continued with [IMP] decreasing to pre-DNP levels and was 
significantly greater with AMPD3 in both vehicle (from undetectable) and DNP (10-fold) 
compared to GFP groups (Fig. 3e). DNP groups had significantly less AN+IMP than vehicle 
groups, yet no differences existed between AMPD3 and GFP groups (Fig. 3f). These results 
show that 1 hour after DNP treatment [ADP], [AMP], AMP:ATP, and [IMP] return back to 
steady-state levels, suggesting that the myotubes are still viable because they have begun the 
recovery process.  
The deamination of AMP to IMP is catalyzed by AMPD and is the entry reaction for the 
purine nucleotide cycle. The purine nucleotide cycle is a multistep process that leads to the 
reamination of IMP to AMP with an amine group donated from aspartic acid (Figure 2 in lit. 
review). Therefore, aspartic acid concentrations can be used an indirect measure of purine 
nucleotide cycle activity. In the same samples that we collected for measurements of nucleotide 
content, we also measured aspartic acid concentration (Figure 4). After a 1 hour treatment with 




recovery period the concentration of aspartic acid in DNP treated myotubes had decreased 
significantly below levels of the vehicle treated myotubes (Fig. 4b). No differences were 
measured between GFP and AMPD3 at either time point. These findings suggest that during an 
energy demand purine nucleotide cycle is relatively inactive but after a short recovery period (1 
hr.) activity resumes, presumably to increase reamination of IMP to AMP and maintain 
intracellular concentration of the adenine nucleotide pool.  
We show that AMPD3 attenuates the increase in [AMP] during a cellular energy demand 
induced by DNP (Figure 2). Therefore, we next collected proteins under the same conditions to 
determine if the attenuated increase in [AMP] would decrease the phosphorylation of 
AMPK(Thr172), as well as, the phosphorylation of several AMPK downstream targets (Figure 
5). As expected, DNP treatment significantly increased the amount of phosphorylated AMPK 
(pAMPK) and the ratio of phosphorylated AMPK to total AMPK (Fig. 5b & 5c). However, 
overexpression of AMPD3 limited the increase in pAMPK in both vehicle and DNP conditions, 
which together resulted in a significant main effect decrease compared to GFP groups. 
Importantly, we also confirmed that AMPD3 was overexpressed (Fig. 5d). DNP significantly 
increased the phosphorylation of downstream AMPK targets, unc-51-like kinase 1 (ULK1) and 
acetyl CoA carboxylase (ACC), however, no significant differences were detected between 
AMPD3 and GFP groups (Fig. 5f & 5g). The differences in pAMPK (Fig. 5b) along with the 
attenuated increase in the AMP:ATP ratio (Fig. 2d) indicate that AMPD3 overexpression can 
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Figure 1. DNP decreases cellular energetics in a dose dependent fashion. C2C12 myotubes were 
treated with 0, 0.4, 0.6, 0.8, and 1 mM concentrations of 2,4 dinitrophenol (DNP) for 1 hour. 
Nucleotides were extracted immediately after treatment. A-C. Adenine nucleotide concentrations 
normalized to total protein content. D. The calculated ratio of AMP to ATP. 
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Figure 1. DNP decreases cellular energetics in a dose dependent fashion. C2C12 myotubes were 
treated with 0, 0.4, 0.6, 0.8, and 1 mM concentrations of 2,4 dinitrophenol (DNP) for 1 hour. 
Nucleotides were extracted immediately after treatment.  E. IMP concentrations normalized to total 
protein. F. Total adenine nucleotides plus IMP (AN+IMP). 







































* * * * G F P
A M P D 3
B .













* * * *
C .







A M P :A T P
* * * *
D .
 
 Figure 2. AMPD3 prevents increase in ADP and AMP during energy demand. C2C12 
myotubes were transduced with adenovirus encoding either GFP or AMPD3 for 24 hours. At 23 
hours post viral transduction myotubes were treated with 0.6 mM 2,4 dinitrophenol (DNP) or 
vehicle (methanol) for 1 hour. Nucleotides were extracted immediately after DNP treatment and 
measured by UPLC. A-C. Adenine nucleotide concentrations normalized to total protein content. 
D. The calculated ratio of AMP to ATP.  
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Figure 2. AMPD3 prevents increase in ADP and AMP during energy demand. C2C12 
myotubes were transduced with adenovirus overexpressing either GFP or AMPD3 for 24 hours. At 
23 hours post viral transduction myotubes were treated with 0.6 mM 2,4 dinitrophenol (DNP) or 
vehicle (methanol) for 1 hour. Nucleotides were extracted immediately after DNP treatment and 
measured by UPLC. E. IMP concentrations normalized to total protein content. F. Total adenine 
nucleotides with the addition of IMP (AN+IMP). 
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  Figure 3. Cellular energetics recover after an acute bout of DNP. C2C12 myotubes were 
transduced with adenovirus encoding either GFP or AMPD3 for 24 hours. At 23 hours post viral 
transduction myotubes were treated with 0.6 mM 2,4 dinitrophenol (DNP) or vehicle (methanol) 
for 1 hour, and then allowed 1 hour of recovery before extraction. A-C. Adenine nucleotide 
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Figure 3. Cellular energetics recover after an acute bout of DNP. C2C12 myotubes were 
transduced with adenovirus encoding either GFP or AMPD3 for 24 hours. At 23 hours post viral 
transduction myotubes were treated with 0.6 mM 2,4 dinitrophenol (DNP) or vehicle (methanol) 
for 1 hour, and then allowed 1 hour of recovery before extraction. E. IMP concentration normalized 
to total protein content. F. Total adenine nucleotides with the addition of IMP (AN+IMP). 
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Figure 4. Aspartic acid, a substrate of the purine nucleotide cycle, increases during 
energy demand. C2C12 myotubes were transduced with adenovirus encoding either GFP or 
AMPD3 for 24 hours, treated with 0.6 mM 2,4 dinitrophenol (DNP) or vehicle (methanol) for 
1 hour, and then allowed 1 hour of recovery before extraction. A. Aspartic acid concentration 
immediately after DNP treatment. B. Aspartic acid concentrations 1 hour after DNP 
treatment.  
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Figure 5. AMPD3 overexpression limits the phosphorylation of AMPK.  C2C12 
myotubes were transduced with adenovirus encoding either GFP or AMPD3 for 24 hours and 
treated with 0.6 mM 2,4 dinitrophenol (DNP) or vehicle (methanol) for 1 hour. Proteins were 
extracted and expression levels were measured by Western Blot. A. Protein expression levels 
of AMPK. B. Protein expression levels of phosphorylated AMPK (Thr172). C. Calculated 
ratio of phosphorylated AMPK to total AMPK. D. Representative western blot for AMPD3. 
# = main effect of AMPD3 p=0.05, ****= p<0.0001 
GFP      AMPD3       GFP       AMPD3 
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Figure 5. AMPD3 overexpression does not effect phosphorylation of downstream 
AMPK targets ULK1 and ACC. C2C12 myotubes were transduced with adenovirus 
encoding either GFP or AMPD3 for 24 hours and treated with 0.6 mM 2,4 dinitrophenol 
(DNP) or vehicle (methanol) for 1 hour. Proteins were extracted and expression levels were 
measured by Western Blot. E. Protein expression levels of ULK1. F. Protein expression 
levels of phosphorylated ULK1 (Ser555). G. Protein expression levels of phosphorylated 
ACC (Ser79). 





Effects of long-term AMPD3 overexpression on PGC-1α and mitochondrial content.  
Changes in mitochondrial content occur in response to repeated increases in PGC-1α 
content and the transcription, translation, and incorporation of mitochondrial proteins into 
existing mitochondria 23,73. Therefore, in order to test the effect of AMPD3 on the activation of 
PGC-1α and mitochondrial content, we overexpressed AMPD3 and treated cells with a long-term 
dosage of DNP. To do this we transduced myotubes with adenovirus encoding AMPD3 or GFP, 
and 24 hours later began a continuous low-dose treatment (100μM) with DNP for 4 days.  
We first sought to determine the effect of long-term AMPD3 overexpression and 
continuous low-dose DNP treatment on the concentration of adenine nucleotides (Figure 6). 
Overexpressing AMPD3 significantly decreased [ATP] (1.3-fold) in both vehicle and DNP 
groups compared to GFP (Fig. 6a). The low dose DNP treatment did not result in significant 
increases [ADP] and no differences were measured between AMPD3 and GFP (Fig. 6b). 
However, DNP significantly increased [AMP], while AMPD3 overexpression caused a 
significant main effect decrease in [AMP] (Fig. 6c). AMPD3 overexpression increased [IMP] in 
both vehicle and DNP groups compared to undetectable in GFP (Fig. 6e). Lastly, AMPD3 
groups had significantly less AN+IMP in both vehicle (1.3-fold) and DNP (1.2-fold) groups (Fig. 
6f). These results show that long-term overexpression of AMPD3 during continuous low-dose 
DNP treatment can result in significantly decreased [ATP], [AMP], and the total adenine 
nucleotide pool (AN+IMP).  
Muscle cells typically adapt to decreases in [ATP], such as in Figure 6, by increasing 
expression of PGC-1α and subsequently increasing mitochondrial biogenesis 23. Therefore, we 
measured the activity of the PGC-1α promotor region by transfecting C2C12 myoblasts with 




luciferase protein 29. Transfected myoblasts were switched to differentiation media, and AMPD3 
was overexpressed by adenovirus 24 hours after transfection. On the fifth day of overexpression, 
myotubes were lysed and luciferase activity was measured (Fig. 7b). Myotubes overexpressing 
AMPD3 had significantly less luciferase activity compared to those overexpressing GFP 
(p<0.005). These results show that a chronic overexpression of AMPD3 is sufficient to decrease 
PGC-1α promotor region activity and, since PGC-1α can regulate mitochondrial biogenesis, 
suggest that AMPD3 could regulate mitochondrial content.  
Therefore, we next examined the effects of AMPD3 overexpression on mitochondrial 
content by treating live myotubes with fluorescent stains specific for mitochondria (MitoTracker 
green) and nuclei (Hoechst 33343) (Figure 8). Before staining myotubes were treated with 
adenovirus overexpressing AMPD3 or RFP (control) for 5 days, as well as, a 4-day continuous 
treatment of 100 μM DNP. After staining we captured fluorescent images of the myotubes and 
quantified the relative percentage of pixels that emitted green fluorescence as a measure of 
mitochondrial content. DNP treatment significantly increased the percentage of pixels positive 
for green fluorescence. However, myotubes overexpressing AMPD3 had significantly less green 
fluorescence than RFP controls. These findings suggest that DNP treatment for 4 days is capable 
of increasing mitochondrial content in C2C12 myotubes, but overexpression of AMPD3 can 
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Figure 6. Long-term overexpression of AMPD3 decreases ATP and the total adenine 
nucleotide pool. C2C12 myotubes were transduced with adenovirus encoding AMPD3 or GFP 
and then treated with 100μm 2,4 dinitrophenol (DNP) continuously for 4 days. On day 4 of 
DNP treatment (day 5 of overexpression) nucleotides were extracted and analyzed by UPLC. A-
C. Adenine nucleotide concentrations normalized to total protein content. D. The calculated 
ratio of AMP to ATP.  























































Figure 6. Long-term overexpression of AMPD3 decreases ATP and the total adenine nucleotide 
pool. C2C12 myotubes were transduced with adenovirus encoding AMPD3 or GFP and then treated 
with 100μm 2,4 dinitrophenol (DNP) continuously for 4 days. On day 4 of DNP treatment (day 5 of 
overexpression) nucleotides were extracted and analyzed by UPLC. E. IMP concentrations 
normalized to total protein content. F. Total adenine nucleotides plus IMP. 



































































Figure 7. AMPD3 overexpression decreases PGC-1α promotor activity. C2C12 myoblasts were 
transfected with plasmids containing 2Kb of PGC-1α promotor region encoding luciferase protein. 
24 hours after transfection myoblasts were switched to differentiation media. A. Luciferase activity 
in myotubes after 4 days of treatment with 100μM DNP. B. Luciferase activity in myotubes 
























































Figure 8. Myotubes overexpressing AMPD3 have less mitochondria.  After adenovirus 
transduction, myotubes were treated with 100μM DNP for 4 days. Mitochondria and nuclei 
were stained with green and blue fluorescent dyes. Images were captured and percentage of 
pixels positive for green florescence were quantified using ImageJ software.  
**= main effect of DNP p<0.05, #= main effect of AMPD3 p<0.01 
 
 
Chapter 5: Discussion 
DNP treatment creates an ATP supply/demand mismatch and increases mitochondrial content.  
In response to an increase in energy demand such as muscle contractions, or conditions 
where energy production is impaired such as ischemia or mitochondrial dysfunction, the 
hydrolysis of ATP will outpace ADP phosphorylation causing an increase in [ADP] 60. If the 
energy demanding conditions continue, [AMP] will increase due to the near equilibrium reaction 
of adenylate kinase (ADP + ADP ↔ ATP+AMP) which is critical to maintain the ADP:ATP 
ratio and preserve the free energy of ATP hydrolysis 65. Increasing [AMP] will then activate the 
AMPD reaction (AMP→IMP+NH3) and cause an increase in [IMP] 
34. We found that increasing 
DNP concentrations up to 1 mM caused a curvilinear decrease in [ATP], and increase in [AMP], 
AMP:ATP, and [IMP]. Interestingly [ADP] peaked at 0.6 mM DNP but then decreased with 0.8 
and 1 mM concentrations. This could be the result of the significant decrease in total AN+IMP 
that occurred during the 0.8 and 1 mM concentrations. All together our results show that 
treatment with a mitochondrial uncoupler such as DNP is sufficient to decrease cellular energy 
and create similar energetic profiles that are seen during prolonged or intense exercise 87. In turn, 
this causes increases in phosphorylated AMPK (Thr172) (Fig. 5b), PGC-1α promotor region 
activity (Fig. 7a), and mitochondrial content (Fig. 8). These results agree with an in vivo study 
that found supplementing DNP into rat chow for 28 days could increase the mRNA expression 
for several genes and proteins involved in mitochondrial biogenesis including PGC-1α , NRF-1, 
Tfam, citrate synthase, and several other mitochondrial proteins 88. 
AMPD3 overexpression during short term energy demand 
While the degradation of AMP is critical to preserve cellular free energy during intense 




mitochondrial biogenesis through enhancing phosphorylation of AMPK(Thr172) 25,26,89. During 
atrophy AMPD3 expression is significantly increased in skeletal muscle, but whether its 
overexpression is sufficient to decrease [AMP] and phosphorylation of AMPK(Thr172) were 
unknown. To test this we used C2C12 myotubes as an in vitro model of skeletal muscle and then 
overexpressed AMPD3 using an adenovirus. During resting conditions [AMP] is low in skeletal 
muscle 65,86. Therefore, in order to determine the effect of AMPD3 overexpression, we had to 
increase [AMP] by creating an energy demand. Our results show that in response to decreases in 
[ATP], AMPD3 overexpression is sufficient to significantly attenuate increases in [ADP], 
[AMP], and the AMP:ATP ratio (Figure 2). However, while [AMP] and the AMP:ATP ratio 
were significantly less in DNP-AMPD3 compared to DNP-GFP, they were still higher than both 
vehicle groups and this could explain why we only observed a significant main effect when 
measuring the amount of phosphorylated AMPK(Thr172) (Figure 5). For instance, the 
concentration of [AMP] increased 2.9-fold from Veh-GFP to DNP-AMPD3 while the AMP:ATP 
ratio increased 7.2-fold from Veh-GFP to DNP-AMPD3. Not surprisingly this resulted in 
dramatic increases in the amount of phosphorylated AMPK, which suggests that AMPK is highly 
sensitive to increases in [AMP] and the AMP:ATP ratio. This could mean that our comparison of 
phosphorylated AMPK(Thr172) between DNP-GFP and DNP-AMPD3 is a measure of AMPK 
proteins that are completely phosphorylated to those that are only slightly less phosphorylated. If 
so, then possibly a DNP concentration between 0.4 and 0.6 mM might have resulted in 
significantly less phosphorylated AMPK(Thr172) in DNP-AMPD3 vs DNP-GFP.  
Apart from measures of phosphorylated AMPK(Thr172) content, we also measured the 
phosphorylation of several downstream targets of AMPK such as Acetyl CoA Carboxylase 




phosphorylated AMPK we did not measure any differences in the amount of phosphorylated 
ACC and ULK1 between AMPD3 and GFP groups after the DNP treatment. We did however see 
a significant increase in the phosphorylation of these proteins in myotubes treated with DNP. 
This agrees with the evidence that these proteins are targeted by AMPK during times of energy 
demand 61,79,80. ACC catalyzes the formation of malonyl-CoA from cytosolic acetyl-CoA and 
therefore functions to inhibit fatty-acid oxidation by increasing cellular malonyl-CoA levels, 
which inhibits CPT1 and the transport of fatty acids into the mitochondria for β-oxidation90. 
When phosphorylated by AMPK during times of energy demand, ACC becomes inactive and 
thus fatty acids are oxidized in the mitochondria via β-oxidation to generate ATP. On the other 
hand, ULK1 is phosphorylated by AMPK on serine 317, 555, and 777 residues which initiates 
the formation of the autophagosome and protein degradation via autophagy 79,80. Therefore, 
while these proteins are downstream targets of AMPK and thus can be considered a measure of 
AMPK activation, they are not known to regulate mitochondrial biogenesis and do not rule out 
the possibility that AMPK targets that do contribute to mitochondrial biogenesis, such as PGC-
1α , could be less phosphorylated when AMPD3 is overexpressed. Further measures of AMPK 
activity, such as direct AMPK enzyme activity and phosphorylation of PGC-1α on AMPK 
targeted residues, should be measured to further determine AMPK activity when AMPD3 is 
overexpressed.  
The purpose of our study was similar to another that investigated AMP metabolism and 
the activation of AMPK in HEK293T kidney cells 91. In this study by Plaideau et al., HEK293T 
cells were transfected with plasmids encoding AMPD1, AMPD2, and cytosolic 5’ nucleotidase 
IA (cN-IA). They then serum starved the HEK293T cells for 4 hours with DMEM containing 




They found that serum starvation using a low glucose concentration along with oligomycin 
treatment was sufficient to increase [ADP], [AMP], AMP:ATP ratio, and the activity of AMPK. 
Transfecting plasmids that encode AMPD1, AMPD2, and cN-IA resulted in attenuated increases 
in [ADP], [AMP], AMP:ATP ratio, and the activity of AMPK. However, only cells transfected 
with cN-IA expressing plasmids had significant reductions in these measures. The inability of 
AMPD1 and AMPD2 transfection to result in significant decreases in [ADP], [AMP], and 
AMPK activity could be explained by the fact that AMPD1 and AMPD2 are not typically 
expressed in kidney cells 92.  
Increased Purine Nucleotide Cycle activity 
The purine nucleotide cycle (PNC) has several important physiological functions 
including: 1) regulation of the relative AMP, ADP, and ATP levels through the removal of AMP 
to IMP 87, 2) regulation of phosphofructokinase activity by elevations in ammonia 93, 3) 
generation of citric acid cycle intermediates 83,94,  and 4) deamination of amino acids for 
oxidative metabolism 95. The activity of the PNC is dependent on the rate of AMPD activity, and 
therefore AMPD3 overexpression could potentially lead to increased PNC activity, aspartic acid 
catabolism, and citric acid cycle flux. In fact, a recent study found that AMPD3 overexpression 
in C2C12 myotubes can significantly increase rates of aspartic acid oxidation, fatty acid 
oxidation, and oxygen consumption during electrical pulse stimulation 96. We found that a 1 hour 
treatment with DNP increased aspartic acid concentrations significantly, and following a 1 hour 
recovery period they return back to resting levels (Figure 4). The dramatic increase in aspartic 
acid and IMP concentrations after DNP treatment suggests that the PNC is either slower or 




return of aspartic acid and IMP concentrations to values similar to vehicle groups suggests that 
during the recovery the PNC is active.  
AMPD3 overexpression during long term energy demand 
A downstream target of AMPK is the transcriptional co-activator PGC-1α, which is an 
established activator of mitochondrial biogenesis in skeletal muscle. AMPK has been shown to 
phosphorylate PGC-1α on threonine 177 and serine 538 residues which will stimulate PGC-1α to 
translocate to the nucleus where it will interact with transcription factors such as PPAR and 
NRF-1 23,29. These transcription factors regulate the gene expression of several nuclear encoded 
mitochondrial proteins and upon binding by PGC-1α increase their transcription. PGC-1α  has 
also been shown to increase the transcription of its own gene sequence after phosphorylation by 
AMPK 27. Therefore by measuring the promotor region activity of PGC-1α, we can acquire a 
sensitive indirect measure of PGC-1α expression and activity. We found that AMPD3 
overexpression for 5 days decreases PGC-1α promotor region activity (Fig. 7b), which could also 
suggest that less cytosolic PGC-1α translocated to the nucleus after phosphorylation by AMPK. 
PGC-1α can also be activated by deacetylation by SIRT1. Therefore, further measures of 
decreased PGC-1α activation, such as less mRNA and protein content, phosphorylation and 
acetylation on AMPK or SIRT1 targeted residues, and decreases in the ratio of nuclear to 
cytosolic PGC-1α, would add convincing evidence to support AMPD3 regulation of PGC-1α. 
Our main hypothesis is that AMPD3 overexpression can negatively regulate 
mitochondrial content in skeletal muscle. By quantifying the relative percentage of mitochondrial 
fluorescence in images from myotubes treated for four days with 100 μM DNP, we found 
significant decreases in percentages of fluorescence when AMPD3 was overexpressed compared 




mitochondrial content in skeletal muscle, however, several other measures of mitochondrial 
content are needed to confirm this finding because mitochondrial are may not translate to 
mitochondrial enzymes or oxidative capacity. Other measures of mitochondrial content that 
could be performed include: 1) mRNA and protein content for mitochondrial proteins such as 
citrate synthase, succinate dehydrogenase, and oxidative phosphorylation enzymes, 2) 
incorporation of radiolabeled amino acids into mitochondrial proteins to determine rates of 
mitochondrial protein synthesis, 3) mitochondrial DNA content relative to nuclear DNA, and 4) 
maximal oxygen consumption.    
In conclusion, we found that a short-term overexpression of AMPD3 can significantly 
attenuate increases in [AMP] and phosphorylation of AMPK(Thr172) during energy demand. 
Furthermore, a long-term overexpression of AMPD3 can significantly decrease PGC-1α 
promotor region activity and mitochondrial content in C2C12 myotubes. These findings indicate 
that AMPD3 is possibly a novel regulator of mitochondrial content in skeletal muscle. Selective 
inhibition of AMPD3 in skeletal muscles undergoing atrophy could potentially preserve 
mitochondrial content and muscle function. This may allow patients to maintain exercise 
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